These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

615 related items for PubMed ID: 19205838

  • 1. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
    Sato M, Okumura T, Kaito K, Kiyoshima M, Asato Y, Uchiumi K, Iijima H, Hashimoto I, Kaburagi T, Amemiya R.
    Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. 18F-FDG PET/CT for staging of penile cancer.
    Scher B, Seitz M, Reiser M, Hungerhuber E, Hahn K, Tiling R, Herzog P, Reiser M, Schneede P, Dresel S.
    J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528
    [Abstract] [Full Text] [Related]

  • 4. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S.
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [Abstract] [Full Text] [Related]

  • 5. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
    Spratt DE, Diaz R, McElmurray J, Csiki I, Duggan D, Lu B, Delbeke D.
    Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
    [Abstract] [Full Text] [Related]

  • 6. Computer-aided detection (CAD) and assessment of malignant lesions in the liver and lung using a novel PET/CT software tool: initial results.
    Hahn S, Heusner T, Zhou X, Zhan Y, Peng Z, Hamami M, Forsting M, Bockisch A, Antoch G.
    Rofo; 2010 Mar; 182(3):243-7. PubMed ID: 19859858
    [Abstract] [Full Text] [Related]

  • 7. F-18 FDG PET/CT in the management of thyroid cancer.
    Iagaru A, Kalinyak JE, McDougall IR.
    Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
    [Abstract] [Full Text] [Related]

  • 8. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C, Ceresoli GL, Rizzo G, Artioli D, Cattaneo M, Castellone P, Gregorc V, Picchio M, Landoni C, Fazio F.
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Usefulness of a breath-holding acquisition method in PET/CT for pulmonary lesions.
    Yamaguchi T, Ueda O, Hara H, Sakai H, Kida T, Suzuki K, Adachi S, Ishii K.
    Ann Nucl Med; 2009 Jan; 23(1):65-71. PubMed ID: 19205840
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
    Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C, Camargo EE.
    J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
    Heusner T, Gölitz P, Hamami M, Eberhardt W, Esser S, Forsting M, Bockisch A, Antoch G.
    Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 17. Objective and subjective comparison of standard 2-D and fully 3-D reconstructed data on a PET/CT system.
    Strobel K, Rüdy M, Treyer V, Veit-Haibach P, Burger C, Hany TF.
    Nucl Med Commun; 2007 Jul 01; 28(7):555-9. PubMed ID: 17538397
    [Abstract] [Full Text] [Related]

  • 18. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ, Zhang YX, Wei H, Jia Q.
    Zhonghua Yi Xue Za Zhi; 2007 Aug 28; 87(32):2253-6. PubMed ID: 18001544
    [Abstract] [Full Text] [Related]

  • 19. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
    Ohno Y, Koyama H, Nogami M, Takenaka D, Yoshikawa T, Yoshimura M, Ohbayashi C, Sugimura K.
    J Magn Reson Imaging; 2007 Oct 28; 26(4):1071-80. PubMed ID: 17896365
    [Abstract] [Full Text] [Related]

  • 20. Dynamic MRI, dynamic multidetector-row computed tomography (MDCT), and coregistered 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/CT: comparative study of capability for management of pulmonary nodules.
    Ohno Y, Koyama H, Takenaka D, Nogami M, Maniwa Y, Nishimura Y, Ohbayashi C, Sugimura K.
    J Magn Reson Imaging; 2008 Jun 28; 27(6):1284-95. PubMed ID: 18504748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.